Frequency and Timeline Dynamics
Endometrial polyp recurrence is a multifaceted phenomenon with rates oscillating widely between 2.5% and 45.5% depending on the study population and follow-up duration. The median interval for regrowth in reproductive-age women is roughly 42.5 months, indicating that surveillance need not be overly aggressive in all cases.
Key clinical drivers of recurrence include morphological factors such as multiple initial polyps and pathological indicators like hyperplastic changes, which carry a hazard ratio (HR) of 2.016 for future recurrence. Chronic conditions including obesity (BMI ≥30), PCOS, and adenomyosis further exacerbate the risk, demanding a personalized monitoring schedule.
Inflammation and Hormonal Modulation
A pivotal discovery in recent years is the role of chronic endometritis (CE) as a persistent driver of polyp development. Evidence suggests that nearly 50% of premenopausal women presenting with polyps exhibit histopathologic signs of CE, with the presence of CE tripling the risk of recurrence (HR 3.08) and increasing the 1-year recurrence rate by over 15%.
While clinicians have historically utilized oral progestins to manage regrowth, current data indicates these interventions have limited efficacy. Conversely, the levonorgestrel-releasing intrauterine system (LNG-IUS) stands out as a high-efficacy intervention (OR 0.043) for preventing recurrence, providing local hormonal stability that oral therapies cannot replicate.